New Guideline Recommends CYP2C19 Genotyping Before Clopidogrel Therapy
Lydia Kariuki, Managing Editor at American Pharmacogenomics Association, posted on LinkedIn:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Feb 13, 2026, 06:01Heghine Khachatryan: Privileged To Participate In the ASH MMENA Partner Societies Leadership Meeting
-
Feb 12, 2026, 16:36Tagreed Alkaltham: Tranexamic Acid in PBM
-
Feb 12, 2026, 16:35Paul Lambis Announces Maria Hadjidemetriou as a Speaker at Cyprus Diaspora Forum
-
Feb 12, 2026, 16:34Rahul Bhargava: Breaking Myths About Bone Marrow Transplant
-
Feb 12, 2026, 16:29Arun V J: Can You Be A Doctor And Still Be Stupid?
-
Feb 12, 2026, 16:26Changing the Narrative Around PPH – End Postpartum Hemorrhage
-
Feb 12, 2026, 16:20Mahesan Subramaniam: The Protective Switch in Brain Immune Cells Could Slow Alzheimer’s Disease
-
Feb 12, 2026, 16:13Lale Tokgözoğlu: Top 10 Dyslipidemia Papers of 2025
-
Feb 12, 2026, 16:10Neelam Mohan: Breaking Down Anemia from Causes and Testing to Treatment and Prevention